Advertisement
UK markets open in 6 hours 14 minutes
  • NIKKEI 225

    38,262.74
    +710.58 (+1.89%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,335.30
    -6.80 (-0.29%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,542.34
    -176.61 (-0.33%)
     
  • CMC Crypto 200

    1,430.53
    +15.77 (+1.11%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.